Tongeren Borgloon

Young adults aged 18 to 25 who experience frequent thoughts about killing themselves are the focus of this study, which evaluates the cost-effectiveness of Attachment Based Family Therapy ABFT compared to Treatment As Usual TAU. Suicide is a leading cause of death among young adults, and current treatments have limited success. This trial aims to determine if involving family through ABFT can better reduce suicidality and improve outcomes, informing clinical guidelines and care practices in Belgium and the Netherlands. Participants are randomly assigned to one of two groups the experimental group receives ABFT as an add-on to TAU, which includes treatments like antidepressants, CBT, or DBT, with weekly ABFT sessions lasting about 16 weeks. The control group receives TAU alone, allowing up to four sessions of systemic family therapy. ABFT focuses on strengthening parent-child attachment bonds to provide a supportive base for young adults, involving parents or caregivers actively in therapy. Throughout the study, suicidality is measured at baseline, immediately after intervention, and at follow-ups 3, 6, and 12 months post-intervention using tools like the Suicidal Ideation Questionnaire Junior. Researchers also assess depressive symptoms, family functioning, attachment, quality of life, and healthcare costs. The trial includes 138 participants across multiple sites, with double-blind randomized allocation. Safety, adherence, and cost-effectiveness are closely monitored during and after the treatment period.

Researchers are studying foot drop caused by peroneal nerve entrapment to determine if decompressive surgery is more effective than maximal conservative treatment. This trial is prospective, multi-center, and randomized, focusing on patients with persistent foot drop lasting about 10 weeks after symptom onset. The study aims to compare recovery in muscle strength and walking ability, with the main measure being the distance walked in six minutes, evaluated 9 months after treatment begins. Participants will be randomly assigned to either decompressive surgery performed within one week after randomization or to conservative treatment involving physiotherapy and gait rehabilitation. Those in the surgical group undergo neurolysis to release the nerve, while the conservative group receives standard care without surgery until the primary endpoint is reached. Follow-up visits occur at multiple time points including 10 days for surgery, 6 weeks, 3, 6, 9, and 18 months to monitor progress. During the study, participants will complete various questionnaires and undergo assessments of muscle strength, gait performance, quality of life, and electrodiagnostic tests. Researchers will track recovery through tests like the six-minute walk and 10-meter walk, muscle strength scores, and patient-reported outcomes. Safety and complications will be monitored throughout, and participants will be observed for up to 18 months post-randomization to gather extended follow-up data.

Pregnancy involves many changes in the cardiovascular system, but in pre-eclampsia PE, these changes are abnormal. PE affects 5 to 8 percent of pregnant women worldwide and is marked by high blood pressure and protein in the urine after 20 weeks of pregnancy. If not treated, PE can cause serious problems for both mother and baby. This research focuses on better monitoring and early detection of PE in high-risk pregnant women. The study compares two groups a control group receiving no intervention, and a remote monitoring group using special devices. At 10 weeks of pregnancy, all participants receive measurements with NICCOMO, maternal venous Doppler echography, and Maltron bio-electronic impedance analysis. These tests repeat at 20 weeks, and at 30 weeks if results are abnormal. The remote monitoring group uses devices to check blood pressure twice daily, activity continuously, and weight once daily. Participants will be monitored throughout their pregnancy with repeated tests and device tracking. Researchers will check blood pressure, heart and vein function, body measurements, activity levels, and weight at specific times. They will also collect birth-related information like birth weight, gestational age, delivery method, and timing. The study includes 2000 pregnant women and aims to improve follow-up and care for those at risk of PE.

Researchers are evaluating how well physiotherapy sessions in Flemish nursing homes follow the IAGG-GARN guidelines and what factors influence physiotherapists clinical practices. The study focuses on multiple nursing homes across the provinces of Limburg, Antwerp, and Flemish Brabant to capture a variety of geographic and organizational settings. It aims to understand the content and volume differences in physiotherapy sessions and to identify challenges and supports physiotherapists face when applying these guidelines. The study involves observing routine physiotherapy sessions delivered by licensed physiotherapists in these nursing homes. Researchers will document session details such as content, duration, exercise type, use of equipment, supervision levels, intensity, and other factors over a two-week period using structured diaries. Participating physiotherapists will also join focus groups to discuss their experiences, barriers, facilitators, and decision-making related to guideline-based care. Participants will be monitored through direct observation and focus group discussions. The main outcome is the adherence to IAGG-GARN guidelines within two weeks. Secondary measures include detailed exercise descriptions, equipment use, group size, supervision level, exercise timing, rest periods, intensity, and contextual factors. The study is observational, with no treatments assigned, and aims to provide insights into real-world physiotherapy practices and guideline implementation in Flemish nursing homes.

The trial investigates treatment options for adults with inflammatory bowel diseases IBD, including Crohns disease and ulcerative colitis, focusing on patients who were previously treated with an optimized dose of intravenous infliximab. The study aims to compare if switching to weekly subcutaneous infliximab leads to better clinical and biological remission outcomes than the standard bi-weekly subcutaneous administration. It also compares patients willing to switch to subcutaneous treatment with those continuing intravenous therapy. Participants who switch from intravenous infliximab will be randomly assigned to receive either 120 mg of subcutaneous infliximab weekly or every other week. Those not willing to switch will continue their existing intravenous dosing schedule. The study is conducted nationally with multiple centers, involving screening and follow-up visits over one year, with physical exams, clinical scoring, blood and stool analyses, and questionnaires about quality of life and treatment satisfaction. During the study, participants will have four visits with their gastroenterologist throughout one year, where clinical remission scores, lab tests, and medication use are assessed. Those on subcutaneous infliximab will keep a diary of at-home injections and complete satisfaction questionnaires. The primary measurement is the proportion of patients maintaining steroid-free clinical and biological remission without treatment changes at week 52. Researchers will also monitor treatment optimization, discontinuation, relapse timing, and patient experiences.